-11.8%
PYPL vs GSK
+53.4%
-65.2%
-57.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.2% | -2.7% | -0.5% | -3.0% |
| 7D | +1.7% | -4.2% | +5.9% | +2.1% |
| 30D | -9.7% | -7.5% | -2.2% | -9.2% |
| 3M | +29.2% | -3.3% | +32.5% | +29.6% |
| 6M | +13.9% | -9.3% | +23.2% | +14.6% |
| YTD | -8.1% | +1.6% | -9.7% | -8.6% |
| 1Y | -21.4% | +25.5% | -46.9% | -23.8% |
| 3Y | -11.8% | +49.3% | -61.1% | -17.6% |
| All | -11.8% | +53.4% | -65.2% | -17.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling